People · Operator
Named in public records as an officer, director or promoter · active 2018–2018 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Navitor Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $68.2M | $686.4M | 2018 |
John P. Creecy at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside John P. Creecy on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jean-Francois Formela | 1 | 17 |
| Kevin Bitterman | 1 | 15 |
| Brian Gallagher | 1 | 11 |
| Alan Crane | 1 | 9 |
| Rajeev Dadoo | 1 | 7 |
| Paul Friedman | 1 | 5 |
| John Creecy | 1 | 5 |
| Marian Nakada | 1 | 4 |
| THOMAS HUGHES | 1 | 4 |
| Vinzenz Ploerer | 1 | 4 |
| David Madden | 1 | 3 |
| Vinzenz P. Ploerer | 1 | 2 |
| George P. Vlasuk | 1 | 1 |
| Barry P. Burgdorf | 1 | 1 |
| Rick Lundberg | 1 | 1 |
| David Goldfarb | 1 | 1 |
| George Vlasuk | 1 | 1 |
| Georg Vlasuk | 1 | 1 |
| Richard Lundberg | 1 | 1 |
| Alan P. Crane | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.